Zobrazeno 1 - 10 of 171 pro vyhledávání: '"Dirk J, de Jong"'
1
Akademický článek
Genetic deficiency of NOD2 confers resistance to invasive aspergillosis
Autor: Mark S. Gresnigt, Cristina Cunha, Martin Jaeger, Samuel M. Gonçalves, R. K. Subbarao Malireddi, Anne Ammerdorffer, Rosalie Lubbers, Marije Oosting, Orhan Rasid, Grégory Jouvion, Catherine Fitting, Dirk J. de Jong, João F. Lacerda, António Campos, Willem J. G. Melchers, Katrien Lagrou, Johan Maertens, Thirumala-Devi Kanneganti, Agostinho Carvalho, Oumaima Ibrahim-Granet, Frank L. van de Veerdonk
Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
NOD2 has been shown to be crucial for immune recognition of Aspergillus infection. Here the authors show that a common NOD2 genetic variant associated with Crohn’s disease is associated with reduced risk of disease due to enhanced antifungal activa
Externí odkaz: https://doaj.org/article/b13bbdc0097e4f22afcd8c24f2411e03
Zobrazit plný text záznamu
2
Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy
Autor: Fenna M. Jansen, Lisa J. T. Smits, Pepijn W. A. Thomas, Dirk J. de Jong, Joany E. Kreijne, Willemijn A. van Dop, Nathan den Broeder, Frank Hoentjen
Publikováno v: Jansen, F M, Smits, L J T, Thomas, P W A, de Jong, D J, Kreijne, J E, van Dop, W A, den Broeder, N & Hoentjen, F 2023, ' Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy ', Digestive Diseases and Sciences, vol. 68, no. 7, pp. 2936-2945 . https://doi.org/10.1007/s10620-023-07950-0
Digestive Diseases and Sciences, 68, 7, pp. 2936-2945
Digestive Diseases and Sciences. Springer New York
Contains fulltext : 294343.pdf (Publisher’s version ) (Open Access) BACKGROUND: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2fcf105b2c9522d32ae27ea1439760
https://research.vumc.nl/en/publications/08b520d7-daa6-452a-9978-4d28d3c837c0
Zobrazit plný text záznamu
3
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial
Autor: Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch
Publikováno v: Lancet Gastroenterology & Hepatology, 8, 4, pp. 343-355
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.
Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4a13f67ca392c8811058105e50cf3a
https://repository.ubn.ru.nl/handle/2066/293716
Zobrazit plný text záznamu
4
Akademický článek
Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2.
Autor: Marijn C Visschedijk, Rudi Alberts, Soren Mucha, Patrick Deelen, Dirk J de Jong, Marieke Pierik, Lieke M Spekhorst, Floris Imhann, Andrea E van der Meulen-de Jong, C Janneke van der Woude, Adriaan A van Bodegraven, Bas Oldenburg, Mark Löwenberg, Gerard Dijkstra, David Ellinghaus, Stefan Schreiber, Cisca Wijmenga, Initiative on Crohn and Colitis, Parelsnoer Institute, Manuel A Rivas, Andre Franke, Cleo C van Diemen, Rinse K Weersma
Publikováno v: PLoS ONE, Vol 11, Iss 8, p e0159609 (2016)
Genome-wide association studies have revealed several common genetic risk variants for ulcerative colitis (UC). However, little is known about the contribution of rare, large effect genetic variants to UC susceptibility. In this study, we performed a
Externí odkaz: https://doaj.org/article/c00c57847396489f8f2c78b83b381354
Zobrazit plný text záznamu
5
Akademický článek
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
Autor: Mirthe E van der Valk, Marie-Josée J Mangen, Mirjam Severs, Mike van der Have, Gerard Dijkstra, Ad A van Bodegraven, Herma H Fidder, Dirk J de Jong, C Janneke van der Woude, Mariëlle J L Romberg-Camps, Cees H M Clemens, Jeroen M Jansen, Paul C van de Meeberg, Nofel Mahmmod, Andrea E van der Meulen-de Jong, Cyriel Y Ponsioen, Clemens Bolwerk, J Reinoud Vermeijden, Peter D Siersema, Max Leenders, Bas Oldenburg, COIN study group and the Dutch Initiative on Crohn and Colitis
Publikováno v: PLoS ONE, Vol 11, Iss 4, p e0142481 (2016)
With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related cos
Externí odkaz: https://doaj.org/article/a65838c5657347abb0fa1aa8abe71eed
Zobrazit plný text záznamu
6
Akademický článek
NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis.
Autor: Gerben Ferwerda, Stephen E Girardin, Bart-Jan Kullberg, Lionel Le Bourhis, Dirk J de Jong, Dennis M L Langenberg, Reinout van Crevel, Gosse J Adema, Tom H M Ottenhoff, Jos W M Van der Meer, Mihai G Netea
Publikováno v: PLoS Pathogens, Vol 1, Iss 3, Pp 279-285 (2005)
Infection with Mycobacterium tuberculosis is one of the leading causes of death worldwide. Recognition of M. tuberculosis by pattern recognition receptors is crucial for activation of both innate and adaptive immune responses. In the present study, w
Externí odkaz: https://doaj.org/article/6488f73434ec4f34b39dffefb812df9c
Zobrazit plný text záznamu
7
Akademický článek
LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease.
Autor: Mark M T J Broekman, Hennie M J Roelofs, Frank Hoentjen, Renske Wiegertjes, Nicole Stoel, Leo A Joosten, Dirk J de Jong, Geert J A Wanten
Publikováno v: PLoS ONE, Vol 10, Iss 7, p e0133932 (2015)
Crohn's disease (CD) is a chronic inflammatory disease in which cytokines play a pivotal role in the induction and maintenance of inflammation. Innate cytokine production is genetically determined and varies largely between individuals; this might im
Externí odkaz: https://doaj.org/article/6b1ddfebdae1475bad81d3c780829332
Zobrazit plný text záznamu
8
Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment
Autor: Sofia A. W. van Moorsel, Joany E. Kreijne, Rachel West, Nanne K. H. de Boer, C. Janneke van der Woude, Annemarie C. de Vries, Rozanne de Veer, Gerard Dijkstra, Dirk J. de Jong
Publikováno v: Alimentary Pharmacology and Therapeutics, 50(4), 407-415
Kreijne, J E, de Veer, R C, de Boer, N K, Dijkstra, G, West, R, Moorsel, S A W, de Jong, D J, van der Woude, C J, de Vries, A C & of the Dutch Initiative on Crohn, Colitis (ICC) 2019, ' Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment ', Alimentary Pharmacology and Therapeutics, vol. 50, no. 4, pp. 407-415 . https://doi.org/10.1111/apt.15402
Alimentary Pharmacology & Therapeutics, 50, 4, pp. 407-415
Alimentary Pharmacology & Therapeutics, 50, 407-415
Alimentary Pharmacology & Therapeutics, 50(4), 407-415. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics, 50(4), 407-415. Wiley
BACKGROUND: Low-dose thiopurine-allopurinol (LDTA) combination therapy is a commonly applied optimisation strategy in IBD patients with a skewed thiopurine metabolism.AIM: To assess continued LDTA maintenance treatment at annual intervals and explore
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba9ba6554afb892a990eb16e6ed0307
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85069934403&origin=inward
Zobrazit plný text záznamu
10
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
Autor: Lauranne A A P Derikx, Lennard P L Gilissen, Moniek H P Gorter, Adriaan C.I.T.L. Tan, Tessa E H Römkens, Marten A Lantinga, Eric R C Halet, Rachel L. West, Jeroen M. Jansen, Rob H. Creemers, Carmen S. Horjus, Meike M C Hirdes, Dirk J. de Jong, Bindia Jharap, Adriaan A. van Bodegraven, Nofel Mahmmod, M. W. M. D. Lutgens, Alexander Bodelier, Ludger S M Epping Stippel, Frank Hoentjen, Sjoukje Nauta, Maarten A van Dijk, Willemijn A van Dop, Paul J. Boekema, Maurice G. Russel
Publikováno v: Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 15, 529-539
Journal of Crohn's and Colitis, 15, 4, pp. 529-539
Journal of Crohns and Colitis
Background and Aims The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we det
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23126db91e69b27ddeeac9dbfac1b073
https://doi.org/10.1093/ecco-jcc/jjaa215
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje